Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India

Background. In 2002, the Meningitis Vaccine Project (MVP) chose the Serum Institute of India, Ltd (SIIL), as its manufacturing partner to establish a product development partnership (PDP) with the Meningitis Vaccine Project (MVP). MVP was a collaboration between PATH and the World Health Organizatio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Infect Dis
Autori principali: Kulkarni, Prasad S., Socquet, Muriel, Jadhav, Suresh S., Kapre, Subhash V., LaForce, F. Marc, Poonawalla, Cyrus S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2015
Soggetti:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639485/
https://ncbi.nlm.nih.gov/pubmed/26553678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ500
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi